Jazz Pharmaceuticals v. Teva et al.: Cannabinoid Epilepsy Patent Dispute — Apotex Claims Dismissed
Jazz Pharmaceuticals Research UK Limited brought patent infringement claims against Teva, Apotex, and over a dozen other generic manufacturers over US11633369B2, covering the use of cannabinoids in epilepsy treatment. After 566 days, Jazz and Apotex stipulated to dismiss all claims between them without prejudice — while litigation continues against the remaining defendants.
Multi-defendant cannabinoid patent battle: Jazz drops Apotex, litigation continues
Filed on 21 July 2023 in the U.S. District Court for the District of New Jersey, this case pits Jazz Pharmaceuticals Research UK Limited against a broad coalition of generic pharmaceutical manufacturers — led by Teva Pharmaceutical Industries — in an infringement action centred on US11633369B2. That patent protects the use of cannabinoids in the treatment of epilepsy, a commercially significant designation given the market for cannabis-derived antiepileptic therapies. Co-defendants include API Pharma Tech, Biophore Pharma, InvaGen, Lupin, Cipla, Alkem, Taro, Apotex, MSN Pharmaceuticals, MSN Laboratories, Zenara Pharma, Ascent Pharmaceuticals, and Padagis — a roster consistent with a Paragraph IV ANDA challenge scenario.
The case closed on 6 February 2025 — at least as between Jazz and Apotex. Pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii), the parties filed a joint stipulation dismissing all claims, counterclaims, and affirmative defenses between them without prejudice and without costs. The court expressly retained jurisdiction to enforce any future disputes between Jazz and Apotex relating to the same subject matter. Critically, the stipulation specifies that Jazz’s dismissal of Apotex does not affect claims or defences against any remaining defendant — the broader litigation is ongoing.
The 566-day duration to this partial resolution is not unusual for a complex multi-defendant pharmaceutical patent case, though the selective dismissal of Apotex without prejudice raises questions about what drove it — a confidential licensing arrangement, a settlement with undisclosed terms, or a strategic litigation prioritisation decision are all plausible, but the public record is silent. The without-prejudice designation means Jazz preserves its right to re-file against Apotex if circumstances change, adding a layer of ongoing commercial uncertainty for Apotex’s generic programme.
Filing to Dismissed without Prejudice in 566 days
566 days in court — typical ANDA pharmaceutical patent disputes run 2–4 years to trial
Dismissed without prejudice: what the Jazz-Apotex stipulation means
Rule 41(a)(1)(A)(ii) dismissal: no merits adjudication
A stipulated dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii) is a procedural exit agreed by both parties — the court makes no ruling on patent validity or infringement. The ‘without prejudice’ designation means neither party is bound by any factual or legal finding, and Jazz retains the right to re-assert the same claims against Apotex in a future action. The court’s retained jurisdiction clause is a notable protective provision.
No merits rulingJazz preserves all rights against Apotex and remaining defendants
Dismissal without prejudice is strategically favourable for Jazz: it extinguishes the immediate litigation burden with Apotex while keeping the threat of re-filing alive. The explicit carve-out confirming that claims against all other defendants remain unaffected signals Jazz’s intent to pursue the broader case. If a confidential licence or supply agreement underlies the Apotex dismissal, Jazz may have secured commercial value without a public concession on patent scope.
Rights preservedApotex exits litigation — but without guaranteed freedom to operate
For Apotex, the without-prejudice dismissal provides immediate litigation relief but does not deliver a validity ruling or a covenant not to sue. If Apotex proceeds with its generic cannabinoid-based epilepsy product, it remains exposed to re-litigation under US11633369B2. Any comfort Apotex has likely derives from a confidential side agreement — which the public record does not confirm. The remaining 12+ defendants face no change in their litigation posture.
No invalidity rulingSelective dismissal tactics signal Jazz’s multi-front enforcement strategy
The pattern of individually resolving one defendant while pressing forward against others is a common branded-pharma enforcement tactic. It allows Jazz to potentially negotiate entry-date agreements or licences defendant-by-defendant while maintaining litigation pressure on hold-outs. For the generic industry broadly, US11633369B2 remains fully in force and actively asserted — no claim has been invalidated, and the patent’s scope over cannabinoid epilepsy methods is unresolved by this partial exit.
Patent fully in forceFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED | Individual | Pharmaceutical IP licensor — holder of US11633369B2 covering cannabinoid epilepsy therapySearch in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Teva Pharmaceutical Industries Ltd. and 12 other generic manufacturers challenging Jazz’s cannabinoid epilepsy patentSearch in Eureka ↗ |
| Co-Defendant | API Pharma Tech, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Biophore Pharma, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Invagen Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Others too numerous to list: LUPIN LTD., CIPLA LTD., ALKEM LABORATORIES LTD., CIPLA USA, INC., ASCENT PHARMACEUTICALS, INC. | Company | Search in Eureka ↗ |
| Co-Defendant | Taro Pharmaceutical Industries, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Apotex, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Laboratories Private, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Zenara Pharma Private, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Padagis US, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for JAZZ PHARMACEUTICALS RESEARCH UK LIMITEDSearch in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for JAZZ PHARMACEUTICALS RESEARCH UK LIMITEDSearch in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for JAZZ PHARMACEUTICALS RESEARCH UK LIMITEDSearch in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for JAZZ PHARMACEUTICALS RESEARCH UK LIMITEDSearch in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing JAZZ PHARMACEUTICALS RESEARCH UK LIMITEDSearch in Eureka ↗ |
| Defendant counsel | Christine Intromasso Gannon | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Lauren Ruth Malakoff | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Liza M. Walsh | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal is expressly limited to the Jazz-Apotex relationship and explicitly preserves all claims against every other named defendant. The without-prejudice formulation means no estoppel arises — Jazz may re-assert US11633369B2 against Apotex in a future action without being bound by any prior ruling. The court’s retained jurisdiction clause is a non-standard provision that effectively creates an expedited re-engagement mechanism. No merits determination was made on patent validity, infringement, or claim scope.
US11633369B2 — Use of cannabinoids in the treatment of epilepsy
US11633369B2 (application number US17/819046) protects the use of cannabinoids — likely cannabidiol (CBD) or related cannabinoid compounds — in the treatment of epilepsy. This patent sits within the fast-growing clinical cannabis therapeutics space, where CBD-based drugs such as Epidiolex have demonstrated regulatory approval for specific epilepsy syndromes including Dravet syndrome and Lennox-Gastaut syndrome. The patent’s claims over treatment methods are particularly defensible in the Hatch-Waxman context, where method-of-use Orange Book listings can trigger infringement liability for ANDA filers whose labelling encompasses the protected indication.
The breadth of the defendant list — encompassing finished-dose manufacturers, API suppliers, and international generics players — suggests the patent is considered a significant commercial barrier to generic entry in the cannabinoid epilepsy treatment market. Jazz’s decision to assert this patent aggressively against over a dozen defendants in New Jersey is consistent with a strategy to protect exclusivity in a market where brand revenues are material. For competitors developing cannabinoid-based antiepileptic products, US11633369B2 represents a meaningful FTO risk that warrants claim-level analysis, particularly around dosing regimens, patient populations, and titration protocols that may distinguish over asserted claims.
Should your team run an FTO against US11633369B2?
Any R&D team developing, formulating, or commercialising cannabinoid-based therapies for epilepsy — whether as a finished dose product or as an API supplier — should treat US11633369B2 as a priority FTO target. The Apotex dismissal without prejudice does not establish any safe harbour. With over a dozen generic manufacturers still in active litigation, the patent’s enforceability and claim scope remain live and contested. Companies with pending ANDAs or those planning Paragraph IV certifications against Jazz’s Orange Book listings are at particular risk if their proposed labelling overlaps with the protected indication.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US11633369B2 against your specific product formulation, dosing method, and patient population parameters — identifying design-around opportunities or claim limitations that may narrow your exposure. Eureka also enables real-time monitoring of related continuation applications and litigation developments, so your legal and R&D teams are never operating on stale intelligence in a rapidly evolving enforcement environment.
Run a freedom-to-operate analysis on US11633369B2 to assess your product’s exposure
Run FTO in Eureka →Similar cannabinoid pharmaceutical patent cases in federal district courts
Cases involving cannabinoid and CBD-based pharmaceutical patents litigated in New Jersey and other federal courts under the Hatch-Waxman framework.
What this case signals for the cannabinoid pharma IP landscape
Jazz’s multi-defendant enforcement of a cannabinoid epilepsy patent in New Jersey reflects intensifying IP competition in the emerging cannabis-derived therapeutics sector.
Without-prejudice exits leave generic manufacturers in legal limbo
Apotex’s exit without a validity ruling or covenant not to sue means its commercial planning for any generic cannabinoid epilepsy product carries residual legal risk. Generic manufacturers negotiating selective dismissals should prioritise explicit freedom-to-operate assurances or contractual entry-date commitments as conditions of any settlement.
US11633369B2 remains an active enforcement threat for all remaining generic filers
With Teva, Lupin, Cipla, Alkem, Taro, MSN, InvaGen, Zenara, Ascent, Padagis, API Pharma Tech, and Biophore still named, the litigation scope is substantial. Any generic manufacturer with an ANDA referencing cannabinoid-based epilepsy indications should assess its exposure to this patent before progressing towards a launch date.
LIMITED v Teva — key questions answered
The claims between Jazz Pharmaceuticals Research UK Limited and Apotex Inc. were dismissed without prejudice by joint stipulation under Fed. R. Civ. P. 41(a)(1)(A)(ii) on 6 February 2025. No costs or attorneys’ fees were awarded. The court retained jurisdiction to resolve future disputes between Jazz and Apotex. Litigation continues against all other named defendants.
Jazz asserts US11633369B2 (application US17/819046), which covers the use of cannabinoids in the treatment of epilepsy. This is a method-of-use patent relevant to the Hatch-Waxman ANDA framework, where an Orange Book listing can trigger a 30-month stay and infringement liability for generic filers whose proposed labelling encompasses the protected indication.
No. A dismissal without prejudice contains no validity ruling, no finding of non-infringement, and no covenant not to sue. Apotex retains litigation risk under US11633369B2 and Jazz may re-file claims against it. Any operational comfort Apotex has likely derives from a confidential agreement not reflected in the public record. Other generic manufacturers should not treat this dismissal as establishing any precedent on patent scope.
The case names Teva Pharmaceutical Industries, API Pharma Tech, Biophore Pharma, InvaGen Pharmaceuticals, Lupin, Cipla, Alkem Laboratories, Cipla USA, Ascent Pharmaceuticals, Taro Pharmaceutical Industries, Apotex, MSN Pharmaceuticals, MSN Laboratories, Zenara Pharma, and Padagis US — a broad coalition consistent with a multi-ANDA Hatch-Waxman infringement action.
The New Jersey District Court’s retention of jurisdiction over Jazz-Apotex disputes means Jazz can return to the same court to enforce any agreement reached between the parties or to re-litigate if a triggering event occurs — without needing to file a new case from scratch. This is a commercially significant provision that shortens Jazz’s enforcement path and may reflect milestone-based conditions in a confidential side agreement.
PatSnap Eureka searches patents and litigation data to answer instantly.